Angiosarcoma of the Head and Neck

Abstract

Introduction Angiosarcoma of the head and neck is a rare vascular sarcoma associated with high rates of local recurrence and distant metastasis and a poor prognosis.

Objective We describe our experience treating patients with angiosarcoma of the head and neck to evaluate the outcomes, patterns of failure, and current treatments.

Methods We identified six patients with angiosarcoma of the head and neck and treated at our institution between 2000 and 2013. We compared our results to the literature from 1979 to 2013.

Results Mean follow-up was 42 months. Local recurrence rate was 50% with disease-specific survival and 2-year disease-free survival rates of 33.3 and 20%, respectively. Prognostic factors included tumor size > 5 cm and surgical margin status, with no correlation between histologic grade and survival. Combined-modality therapy was only used for aggressive tumors with positive surgical margins but is suggested to improve local control and overall survival.

Conclusions Our data series supports that angiosarcoma of the head and neck has a high rate of recurrence and is associated with a poor prognosis, despite current combined-modality therapy. The study highlights the importance of attaining negative margins during surgical resection, the utility of adjuvant therapies, as well as the need for continued research in developing new management strategies.

Keywords

angiosarcoma - head and neck neoplasms - radiotherapy - surgery

• References

• 1 Lydiatt WM, Shaha AR, Shah JP. Angiosarcoma of the head and neck. Am J Surg 1994; 168 (5) 451-454
• 2 Holden CA, Spittle MF, Jones EW. Angiosarcoma of the face and scalp, prognosis and treatment. Cancer 1987; 59 (5) 1046-1057
• 3 Pawlik TM, Paulino AF, McGinn CJ , et al. Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer 2003; 98 (8) 1716-1726
• 4 Fury MG, Antonescu CR, Van Zee KJ, Brennan MF, Maki RG. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 2005; 11 (3) 241-247
• 5 Mark RJ, Tran LM, Sercarz J, Fu YS, Calcaterra TC, Juillard GF. Angiosarcoma of the head and neck. The UCLA experience 1955 through 1990. Arch Otolaryngol Head Neck Surg 1993; 119 (9) 973-978
• 6 De Yao JT, Sun D, Powell AT, Rehmus EH. Scalp angiosarcoma remission with bevacizumab and radiotherapy without surgery: a case report and review of the literature. Sarcoma 2011; 2011: 160369
• 7 Ogawa K, Takahashi K, Asato Y , et al. Treatment and prognosis of angiosarcoma of the scalp and face: a retrospective analysis of 48 patients. Br J Radiol 2012; 85 (1019) e1127-e1133
• 8 Ohguri T, Imada H, Nomoto S , et al. Angiosarcoma of the scalp treated with curative radiotherapy plus recombinant interleukin-2 immunotherapy. Int J Radiat Oncol Biol Phys 2005; 61 (5) 1446-1453
• 9 Sasaki R, Soejima T, Kishi K , et al. Angiosarcoma treated with radiotherapy: impact of tumor type and size on outcome. Int J Radiat Oncol Biol Phys 2002; 52 (4) 1032-1040
• 10 Perez MC, Padhya TA, Messina JL , et al. Cutaneous angiosarcoma: a single-institution experience. Ann Surg Oncol 2013; 20 (11) 3391-3397
• 11 Guadagnolo BA, Zagars GK, Araujo D, Ravi V, Shellenberger TD, Sturgis EM. Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp. Head Neck 2011; 33 (5) 661-667
• 12 Hodgkinson DJ, Soule EH, Woods JE. Cutaneous angiosarcoma of the head and neck. Cancer 1979; 44 (3) 1106-1113
• 13 Yang P, Zhu Q, Jiang F. Combination therapy for scalp angiosarcoma using bevacizumab and chemotherapy: a case report and review of literature. Chin J Cancer Res 2013; 25 (3) 358-361
• 14 Willers H, Hug EB, Spiro IJ, Efird JT, Rosenberg AE, Wang CC. Adult soft tissue sarcomas of the head and neck treated by radiation and surgery or radiation alone: patterns of failure and prognostic factors. Int J Radiat Oncol Biol Phys 1995; 33 (3) 585-593
• 15 Morrison WH, Byers RM, Garden AS, Evans HL, Ang KK, Peters LJ. Cutaneous angiosarcoma of the head and neck. A therapeutic dilemma. Cancer 1995; 76 (2) 319-327
• 16 Mark RJ, Poen JC, Tran LM, Fu YS, Juillard GF. Angiosarcoma. A report of 67 patients and a review of the literature. Cancer 1996; 77 (11) 2400-2406
• 17 Elias AD, Antman KH. Adjuvant chemotherapy for soft tissue sarcoma: an approach in search of an effective regimen. Semin Oncol 1989; 16 (4) 305-311
• 18 Nagano T, Yamada Y, Ikeda T, Kanki H, Kamo T, Nishigori C. Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients. Cancer 2007; 110 (3) 648-651
• 19 Isogai R, Kawada A, Aragane Y, Tezuka T. Successful treatment of pulmonary metastasis and local recurrence of angiosarcoma with docetaxel. J Dermatol 2004; 31 (4) 335-341
• 20 Karube R, Sasaki H, Shinozuka K , et al. Angiosarcoma of the scalp diagnosed by the presence of neck inflammation: a case report. Int J Oral Sci 2012; 4 (3) 166-169
• 21 Singla S, Papavasiliou P, Powers B , et al. Challenges in the treatment of angiosarcoma: a single institution experience. Am J Surg 2014; 208 (2) 254-259
• 22 Fuller CK, Charlson JA, Dankle SK, Russell TJ. Dramatic improvement of inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapy. J Am Acad Dermatol 2010; 63 (4) e83-e84
• 23 Koontz BF, Miles EF, Rubio MA , et al. Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. Head Neck 2008; 30 (2) 262-266
• 24 Tomita H, Koike Y, Asai M , et al. Angiosarcoma of the scalp successfully treated with pazopanib. J Am Acad Dermatol 2014; 70 (1) e19-e21